In Modern Healthcare’s
article, “House Passes Bipartisan FDA User Fee Bill
,” Partner David Rosen discussed the impact of new legislation passed in the House of Representatives that reauthorizes the FDA’s ability to collect user fees from drug and device makers.
"It gives the FDA predictable resources and allows the industry to have a better understanding of when the FDA will complete reviews, which is very important," Rosen said.
(Subscription may be required to read)